8.96
+0.3119(+3.61%)
Currency In USD
| Previous Close | 8.65 |
| Open | 8.7 |
| Day High | 9.01 |
| Day Low | 8.69 |
| 52-Week High | 14.44 |
| 52-Week Low | 5.03 |
| Volume | 821,529 |
| Average Volume | 1.05M |
| Market Cap | 769.77M |
| PE | -15.72 |
| EPS | -0.57 |
| Moving Average 50 Days | 10.01 |
| Moving Average 200 Days | 9.41 |
| Change | 0.31 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $1,588.99 as of September 30, 2025 at a share price of $8.962. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $1,969.65 as of September 30, 2025 at a share price of $8.962.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
GlobeNewswire Inc.
6 hours ago
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients” Significant improvement in self-
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
GlobeNewswire Inc.
Sep 09, 2025 11:30 AM GMT
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging prof
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
GlobeNewswire Inc.
Sep 02, 2025 11:30 AM GMT
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,